Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly sales of $143.600 million which missed the analyst consensus estimate of $145.832 million by 1.53 percent. This is a 6.61 percent decrease over sales of $153.764 million the same period last year.
Supernus Pharmaceuticals Q1 Sales $143.600M Miss $145.832M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated